Cargando…
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
BACKGROUND: In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we examined the effect of erenumab on reducing acute medicati...
Autores principales: | Tepper, Stewart J, Ashina, Messoud, Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H, Picard, Hernan, Cheng, Sunfa, Chou, Denise E, Zhang, Feng, Klatt, Jan, Mikol, Daniel D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299690/ https://www.ncbi.nlm.nih.gov/pubmed/34301173 http://dx.doi.org/10.1186/s10194-021-01292-w |
Ejemplares similares
-
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018) -
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020) -
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020) -
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020) -
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)